A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Children's Oncology Group
National Institutes of Health Clinical Center (CC)